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Abstract
Background: Chronic hepatitis B is a major health problem and may lead to cirrhosis, liver failure, liver
cancer, and death if untreated. Interferon is currently better than nucleot(s)ide analogues in sustained
seroconversion or loss of HBeAg and HBsAg. Peginterferon prolongs interferon’s effects. This review
compared benefits and risks of peginterferon monotherapy versus peginterferon with lamivudine therapy in
chronic hepatitis B.
Methods: Exhaustive search of medical literature was performed using key words peginterferon,
peginterferon alfa-2a, peginterferon alfa-2b, lamivudine, and chronic hepatitis B, on EBMR Multifile,
Evidence-Based Resources from the Joanna Briggs Institute, Medline-Ovid, and CINAHL. Qualities of
relevant studies were assessed using the GRADE system.
Results: Three randomized controlled trials satisfied inclusion criteria and were included in this review. The
first trial compared efficacy and safety between peginterferon alfa-2a alone, with lamivudine and lamivudine
alone on 537 patients with HBeAg negative chronic hepatitis B. Regarding the viral suppression and the
seroconversion of HBsAg, the groups on peginterferon were better than lamivudine alone; and no significant
differences found between the peginterferon alone and the combination group. The second trial used the same
three types of therapy groups on 814 patients with HBeAg positive chronic hepatitis B. Results were similar to
the first study, plus similar rates of HBeAg loss or seroconversion between the two groups with peginterferon.
The third trial used peginterferon alfa-2b alone or with lamivudine on 307 patients with HBeAg positive
chronic hepatitis B, but final analysis accounted for 266 patients. Both treatment groups were not significantly
different in the rates of responses and safety profile.
Conclusion: Peginterferon alfa-2a or alfa-2b could lead to HBsAg loss or seroconversion and sustained viral
suppression in all chronic hepatitis B patients, and HBeAg loss or seroconversion in HBeAg positive patients.
Peginterferon alone or with lamivudine showed similar responses and side effects. Peginterferon alfa-2a or
alfa-2b were suggested as first line therapy for chronic hepatitis B. Future research is needed to evaluate the
long-term responses of chronic hepatitis B to peginterferon alone or with lamivudine, the benefits of
combining lamivudine to therapy, and the effects of peginterferon alfa-2b in HBeAg negative chronic hepatitis
B patients.
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Abstract   
Background: Chronic hepatitis B is a major health problem and may lead to cirrhosis, 
liver failure, liver cancer, and death if untreated. Interferon is currently better than 
nucleot(s)ide analogues in sustained seroconversion or loss of HBeAg and HBsAg. 
Peginterferon prolongs interferon’s effects. This review compared benefits and risks of 
peginterferon monotherapy versus peginterferon with lamivudine therapy in chronic 
hepatitis B. 
 
Methods: Exhaustive search of medical literature was performed using key words 
peginterferon, peginterferon alfa-2a, peginterferon alfa-2b, lamivudine, and chronic 
hepatitis B, on EBMR Multifile, Evidence-Based Resources from the Joanna Briggs 
Institute, Medline-Ovid, and CINAHL. Qualities of relevant studies were assessed using 
the GRADE system.  
 
Results:  Three randomized controlled trials satisfied inclusion criteria and were included 
in this review. The first trial compared efficacy and safety between peginterferon alfa-2a 
alone, with lamivudine and lamivudine alone on 537 patients with HBeAg negative 
chronic hepatitis B. Regarding the viral suppression and the seroconversion of HBsAg, 
the groups on peginterferon were better than lamivudine alone; and no significant 
differences found between the peginterferon alone and the combination group. The 
second trial used the same three types of therapy groups on 814 patients with HBeAg 
positive chronic hepatitis B. Results were similar to the first study, plus similar rates of 
HBeAg loss or seroconversion between the two groups with peginterferon. The third trial 
used peginterferon alfa-2b alone or with lamivudine on 307 patients with HBeAg positive 
chronic hepatitis B, but final analysis accounted for 266 patients. Both treatment groups 
were not significantly different in the rates of responses and safety profile.  
 
Conclusion: Peginterferon alfa-2a or alfa-2b could lead to HBsAg loss or seroconversion 
and sustained viral suppression in all chronic hepatitis B patients, and HBeAg loss or 
seroconversion in HBeAg positive patients. Peginterferon alone or with lamivudine 
showed similar responses and side effects. Peginterferon alfa-2a or alfa-2b were 
suggested as first line therapy for chronic hepatitis B. Future research is needed to 
evaluate the long-term responses of chronic hepatitis B to peginterferon alone or with 
lamivudine, the benefits of combining lamivudine to therapy, and the effects of 
peginterferon alfa-2b in HBeAg negative chronic hepatitis B patients. 
 
Keywords: peginterferon, peginterferon alfa-2a, peginterferon alfa-2b, lamivudine, 
chronic hepatitis B.  
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Peginterferon Monotherapy versus Peginterferon and 
Lamivudine Combination Therapy for Chronic Hepatitis B  
BACKGROUND 
 
 Despite the efforts of vaccinations and infection control, hepatitis B still remains a 
major health problem.1,2 There are more than 2 billion people around the world infected 
with the hepatitis B virus (HBV), among which, about 600 000 people die yearly due to 
complications of acute or chronic hepatitis B.2 Chronic hepatitis B (CHB) occurs in about 
240 million people worldwide, highest in Sub-Saharan Africa and East Asia, and lowest 
in North America and Western Europe.1  
 Chronic hepatitis B is defined as the positivity of hepatitis B surface antigen 
(HBsAg) lasting longer than 6 months with or without the presence of the hepatitis B 
envelope antigen (HBeAg).1-3 HBeAg positivity indicates that the virus is in high 
replication stage and that the patient's bodily fluids are highly contagious to others.1-4 If 
left untreated, chronic hepatitis B can lead to liver cirrhosis, hepatocellular carcinoma 
(HCC, a type of liver cancer), liver failure, and death.1-6 
 Therefore, it is critically important to treat CHB in order to prevent the above 
complications. Responses to treatment includes virological (HBV DNA suppression), 
serological (HBsAg seroconversion, plus HBeAg seroconversion if HBeAg positive), 
biochemical (normalization of ALT –Alanine  Aminotransferase), and histological 
markers (improved inflammation, necrosis, and fibrosis).3-7 Currently, there are seven 
types of medications approved for CHB treatment: interferon (IFN), peginterferon 
(PegIFN), lamivudine (LAM), adefovir, entecavir, telbivudine, and tenofovir.3-5,7 
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Nucleos(t)ide analogues (the latter listed five drugs, with LAM as a classic and most 
studied drug) are potent antivirals, easier to take (oral form), cheaper to afford, and better 
to tolerate (less adverse events).3-7 Standard interferon can achieve longer post-therapy 
responses, less drug resistance, and higher HBsAg and HBeAg seroconversion than the 
nucleos(t)ide analogues.3-7 With the addition of the polyethylene glycol group to the IFN 
structure, PegIFN results in a slower absorption, metabolism, and clearance, thus 
resulting in a longer half-life than IFN.7 PegIFN provides more sustained 
pharmacological activity and allows less frequent dosing than IFN (weekly versus at least 
three times a week).7  
Currently, there are two kinds of PegIFN, alfa-2a and alfa-2b, with similar effects. 
PegIFN alfa-2a is approved worldwide for treating HBeAg negative and HBeAg positive 
CHB, while PegIFN alfa-2b is only approved in several countries outside the United 
States.7   
 This systematic review compared the efficacy and safety of peginterferon (alfa-2a 
or alfa-2b) alone to peginterferon and lamivudine combination. This review wants to 
investigate if PegIFN monotherapy is as efficacious as the combination therapy, and the 
benefits of the combined therapy in chronic hepatitis B patients, with HBeAg positive or 
negative. 
METHODS 
 An exhaustive literature search was conducted using the following electronic 
databases: Evidence-Based Medicine Reviews Multifile, Evidence-Based Resources from 
the Joanna Briggs Institute, Medline (via Ovid), and CINAHL. Search terms were: 
peginterferon, peginterferon alfa-2a, peginterferon alfa-2b, lamivudine, and chronic 
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hepatitis B. The search was then limited to English-language and human studies, but not 
to time or location of studies. Inclusion criteria of this search were: studies must be in 
adult patients with chronic hepatitis B, who have either HBeAg positive or negative; 
studies must contain the two intervention groups, peginterferon alone (alfa-2a or alfa-2b) 
and peginterferon combined with lamivudine; study design must be blinded randomized 
controlled trials. Exclusion criteria were studies using medications other than 
peginterferon and/or lamivudine for chronic hepatitis B, that were open-labeled, or that 
were not related to chronic hepatitis B treatment.  
 After selecting qualified studies for this review, the studies were critically 
appraised for the validity, results, and risk of bias. Then the quality of studies was 
assessed using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) system.8 
RESULTS 
 There were a total of 388 articles found through initial search. After screening 
those articles using the search terms and exclusion criteria, 16 relevant articles related to 
peginterferon and/or lamivudine therapy in CHB were selected. Out of those 16 studies, 
three studies satisfied all the inclusion criteria and were included in this systematic 
review. For the purpose of this review, the attention focused on comparing the primary 
and important secondary outcomes of the two groups, PegIFN alone and PegIFN with 
LAM, even though some studies may have tested LAM monotherapy as well and 
monitored additional secondary outcomes. All important outcomes were summarized and 
compared in Table 1, Characteristics of reviewed studies, GRADE profile, and summary 
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of findings –peginterferon alone or in combination with lamivudine in chronic hepatitis B 
treatment.  
"Peg 2a in HBeAg Negative" Study (Marcellin et al) 
 This study9 was a partially double-blinded randomized controlled trial which 
assessed the efficacy and safety of peginterferon alfa-2a alone, the combination of 
peginterferon alfa-2a and lamivudine, and lamivudine alone in HBeAg negative chronic 
hepatitis B patients. Study population was 537 patients, aged 18 to 71 years, enrolled 
from 54 sites in 13 countries, mostly in Asia and Europe. Eligibility criteria of enrolled 
patients were: HBeAg negative CHB, anti-HBe Ab and HBsAg positive for at least 6 
months, HBV DNA level greater than 100 000copies/ml, serum ALT level between 1 to 
10 times the upper limit of the normal range, and liver biopsy within the last 24 months 
consistent with CHB, with evidence of prominent necro-inflammation.9 
The patients were randomly assigned into three groups at the ratio 1:1:1, resulting 
in 177 patients given 180mcg/week subcutaneously (SQ) PegIFN alfa-2a plus daily oral 
placebo, 179 patients given 180mcg/week SQ PegIFN alfa-2a plus 100mg/day oral LAM, 
and 181 patients given 100mg/day oral LAM alone. Treatment length was 48 weeks, then 
follow-up was an additional 24 weeks. Patients in all study groups were similar in 
prognostic characteristics at baseline, during, and at the end of treatment. Primary 
outcomes of efficacy were assessed at the end of follow-up: the normalization of ALT, 
and the suppression of HBV DNA to below 20 000copies/ml. Secondary outcomes 
included the HBsAg loss, the HBsAg seroconversion (the loss of HBsAg and the 
presence of anti-HBs antibody), the histologic response on liver biopsy, and the 
suppression of HBV DNA to below 400copies/ml. Safety measures of therapy were 
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monitored at baseline, frequently during treatment, and every 4 weeks during follow-up, 
including the adverse events, hematologic tests, chemical tests, and vital signs.9     
During treatment, ALT flare-up rate was higher in PegIFN-placebo group than in 
PegIFN-LAM group, but it normalized towards the end of follow-up with similar rates: 
59% (95% CI 51.7 to 66.6, P 0.004) in PegIFN-placebo, 60% (95%CI 52.2 to 67.0, P 
0.003) in PegIFN-LAM, with RR=1.01, NNT=100. The suppression of HBV DNA levels 
below 20 000copies/ml was reached with equal rates in both groups: 43% (95%CI 35.5 to 
50.6, P 0.007) in PegIFN-placebo, 44% (95%CI 36.7 to 51.7, P 0.003) in PegIFN-LAM, 
RR=1.02, NNT=100. These primary outcomes appeared lower in LAM alone group.9 
 The study also showed that there was a possibility of achieving the ultimate goal 
of CHB treatment: HBsAg loss and HBsAg seroconversion, which happened in similar 
rates in both groups that had PegIFN. Liver histologic improvements and the suppression 
of HBV DNA levels below 400copies/ml were succeeded at the same percentage of 
patients in both of the PegIFN-placebo and PegIFN-LAM (Table 1) groups.9  
 Patients reported adverse events similarly in both of PegIFN groups, and higher 
than in LAM group, with most common symptoms including pyrexia, fatigue, myalgia, 
and headache. Serious adverse reactions and discontinuation due to safety problems 
showed that PegIFN with or without LAM would have similar safety concerns. There 
were no unexpected adverse effects of the study medications.9  
 The authors discussed that the study was limited in the length of follow-up, which 
was not long enough to evaluate the additional benefits of lamivudine in the combination 
therapy, versus peginterferon monotherapy. They found that there was no significant 
differences in terms of efficacy and safety between peginterferon alfa-2a alone and 
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peginterferon alfa-2a with lamivudine therapies, although both regimens did significantly 
better than lamivudine alone in the suppression of HBV DNA, the loss or seroconversion 
of HBsAg, and the normalization of ALT levels in HBeAg-negative CHB patients. They 
suggested peginterferon alfa-2a as first line therapy for HBeAg negative chronic hepatitis 
B patients due to the possibilities of HBsAg loss or seroconversion.9  
“Peg 2a in HBeAg Positive” Study (Lau et al) 
 The goal of this partially double-blinded randomized controlled trial10 was to 
evaluate the efficacy and safety of peginterferon alfa-2a alone, combination of 
peginterferon alfa-2a and lamivudine, and lamivudine alone in HBeAg positive chronic 
hepatitis B. The study enrolled 814 patients, aged 17 to 77 years, from 67 sites in 16 
countries in Asia, Australia, Europe, North and South America. Inclusion criteria for 
selected patients were: HBsAg positive for at least 6 months, anti-HBs Ab negative, 
HBeAg positive, HBV DNA level greater than 500 000copies/ml, serum ALT level 
between 1 and 10 times the upper limit of the normal range, and liver biopsy within the 
previous 12 months consistent with chronic hepatitis B.10  
 All patients were randomly assigned at the ratio of 1:1:1 into three groups: 271 
patients received SQ PegIFN plus oral placebo, 271 patients received SQ PegIFN plus 
oral LAM,  and 272 patients received oral LAM only. Dosage of PegIFN alfa-2a was 
180mcg/week and of LAM was 100mg/day. Treatment was conducted for 48 weeks, and 
follow-up was for another 24 weeks. Patient characteristics were similar at baseline, and 
prognostic balance was maintained among three groups during and at the end of 
treatment. Primary outcomes at the end of follow-up were the HBeAg seroconversion 
(the loss of HBeAg and the presence of anti-HBe Ab), and the suppression of HBV DNA 
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levels to below 100 000copies/ml. Secondary outcomes were also recorded at end of 
follow-up, including the combined response (the HBeAg seroconversion, the 
normalization of ALT levels, and the suppression of HBV DNA levels to lower than 100 
000copies/ml), the HBsAg seroconversion (the loss of HBsAg and the presence of anti-
HBs antibody), and the histologic response on liver biopsy. The study monitored safety 
of therapies closely at baseline, during treatment and follow-up, including the adverse 
events, hematologic tests, clinical chemical tests, and vital signs.10 
 As the results, primary outcomes did not show significant heterogeneity between 
PegIFN-placebo and PegIFN-LAM groups. HBeAg seroconversion was slightly higher, 
although not significant, in PegIFN-placebo group than in PegIFN-LAM group [32% 
(95%CI 26.6 -38.0, P <0.001) versus 27% (95%CI 22.1 to 33.0, P 0.02), with RR=0.84, 
NNT=20]. The suppression of HBV DNA levels to below 100 000copies/ml was 32% ( 
95%CI 26.2 to 37.6, P 0.01) in PegIFN-placebo group, and 34% (95%CI 28.0 to 39.5, P 
0.003) in PegIFN-LAM group, RR=1.06, NNT=50. These primary outcomes were lower 
in LAM alone group. The recorded combined response of serological, biochemical, and 
virological markers was 23% in PegIFN-placebo group, and 21%in PegIFN-LAM group. 
The rates of HBsAg seroconversion and liver histologic improvement in PegIFN-placebo 
and PegIFN-LAM group were very much the same (Table 1).10  
 Adverse events were also monitored closely in the study. The most common 
symptoms were pyrexia, fatigue, myalgia, and headache. All adverse events were as 
expected and were reported similarly in both PegIFN treatment groups, including serious 
adverse events and therapy discontinuation due to safety reason.10 
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 Similar to the first study, this study's authors did not find any relevant differences 
in benefits or risks between peginterferon alfa-2a alone and peginterferon alfa-2a with 
lamivudine combination. Both treatment regimens showed more benefits than lamivudine 
alone in seroconverting HBeAg and HBsAg, in suppressing HBV DNA levels, and in 
normalizing ALT levels in patients with HBeAg positive CHB. Overall, they suggested 
peginterferon alfa-2a as first line therapy for HBeAg positive chronic hepatitis B, due to 
the possibility of having HBsAg and HBeAg seroconversion, the highest goals of 
treatment for this group of hepatitis B. However, the authors did not discuss limitations of 
the study.10 
 “Peg 2b in HBeAg Positive” Study (Janssen et al)  
 The authors of this double-blinded randomized controlled trial11 wanted to know 
if the combination of lamivudine with peginterferon alfa-2b would increase the rate of 
sustained response in HBeAg positive chronic hepatitis B, as compared to peginterferon 
alfa-2b alone. They enrolled 307 patients, aged 16 years and older, from 42 centers in 15 
countries in Europe, East Asia, and North America. Patients must have all of the 
following eligibility criteria to join the study: HBsAg positive for longer than 6 months, 
HBeAg positive on two occasions within the previous 8 weeks before the randomization, 
two episodes of elevated ALT twice the upper limit of normal range within the previous 8 
weeks before the start of the study.11 
 All patients were randomly allocated into two groups, at 1:1 ratio, 155 patients 
assigned to receive SQ PegIFN alfa-2b plus daily oral placebo, and 152 patients assigned 
to receive SQ PegIFN alfa-2b plus 100mg/day oral LAM. Dosage of PegIFN alfa-2b 
changed from 100mcg weekly for the first 31 weeks to 50mcg weekly for the last 21 
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weeks, and was adjusted to weight if patients weighed 55 kilogram or less. Treatment 
was 52-week long, with 26-week follow-up post-therapy.      
 However, the final analyses included a total of 266 patients, 136 patients in the 
PegIFN-placebo group, and 130 patients in the PegIFN-LAM group, after 41patients 
were excluded from the study (due to misconduct, lost HBeAg before the study started, or 
did not receive study medications). The withdrawal distributed equally among treatment 
groups. Patient characteristics in both study groups were similar at baseline, and the 
prognostic balance was maintained during treatment and at the study's completion. 
Primary end point at the end of follow-up was the loss of HBeAg. Secondary end points 
included the suppression of HBV DNA levels to below 200 000copies/ml, the HBV DNA 
level undetectable (less than 400copies/ml), the normalization of ALT concentrations, 
HBsAg loss or seroconversion, liver histologic response.11This study also assessed the 
HBV genotype and mutation, which are not the focus of this systematic review.  
 At the end of follow-up, the primary end point was homogenous across two study 
groups. The HBeAg loss was at 35% of the PegIFN-LAM group, at 36% of the PegIFN-
placebo group, and not statistically significant between two groups (p = 0.91, α=0.05). 
The HBeAg seroconversion was also similar in both groups (29% in each group, RR =1, 
p=0.92). The rates of suppression of HBV DNA levels to below 200 000copies/ml, the 
HBsAg seroconversion, the HBsAg loss, the undetected HBV DNA levels (below 
400copies/ml), the ALT normalization, and the liver histologic improvements of two 
treatment groups did not reveal relevant differences or statistical significance (all p values 
greater than the significant level α).11 
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Adverse events were expected and similar in PegIFN alone and PegIFN with 
LAM groups. Most common side effects were flu-like symptoms: pyrexia, fatigue, 
myalgia, and headache. All adverse events were reversible after stopping therapy. There 
was not concerning differences of serious adverse effects and therapy discontinuation 
between the two study groups.11  
The study found that peginterferon alfa-2b could cause HBeAg loss and reduction 
of HBV DNA suppression in HBeAg positive chronic hepatitis B patients. However, 
combination peginterferon alfa-2b with lamivudine was not more beneficial than 
peginterferon alfa-2b monotherapy, as all results were not statistically significant 
between treatment groups (p values of all outcomes at end of follow-up were greater than 
0.05). The authors warned the readers to interpret the liver biopsy results carefully, since 
the biopsy was optional for the patients at the end of therapy, and the pool of patients 
who had biopsies may have also been selected.11  
DISCUSSION 
Through the three trials9-11 reviewed above, peginterferon alfa-2a and alfa-2b were 
proven effective in treating chronic hepatitis B, regardless of HBeAg negative or positive 
CHB. These peginterferon forms were found to cause HBsAg loss or seroconversion and 
sustained HBV DNA suppression in both HBeAg positive and negative chronic hepatitis 
B patients,9-11 as well as HBeAg loss or seroconversion10,11 if patients have HBeAg 
positive. On the other hand, these studies did not find additional benefits of adding 
lamivudine to peginterferon therapy. The study results actually showed that the 
peginterferon monotherapy had some outcomes at slightly higher rates and some adverse 
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events at slightly lower rates than did the combination therapy, although those differences 
were not significant.9-11 
However, as we look into the studies closely, there were limitations in these 
studies. There was likely publication bias in all studies. The studies were sponsored 
and/or designed by Roche9,10 or Schering-Plough International and GlaxoSmithKline 
Research and Development.11 The study publications could have been altered by these 
drug companies for their commercial benefits without the authors’ knowledge. However, 
all authors9-11 stated that they had full access to study data and actively performed the 
studies from data collection, analysis, data interpretation, writing the reports, and making 
final decisions for publication. These statements made the bias less severe and the results 
still reliable and useful. Due to this suspected bias, quality of all studies was downgraded 
one level, using the GRADE system (Table 1). 
There was possible selection bias, as mentioned in the result section above, in 
post-therapy liver biopsy in the study of Janssen et al.11 The biopsy occurred at the end of 
the treatment phase and was not a form of treatment, so it did not alter the primary and 
other secondary outcomes, besides the histologic outcome. In this regard, this bias was 
localized within a subset of secondary outcomes, so it did not affect the overall quality of 
this study. Thus, the quality of this study was not downgraded further due to this 
limitation. 
In these three studies,9-11 follow-up lasted from 24 to 26 weeks, which may be 
sufficient for reevaluating the CHB condition and retesting the HBV status once or twice, 
but may be not long enough to fully evaluate the long-term responses of HBV, HBsAg, 
HBeAg, ALT, and liver histology to peginterferon alone or with lamivudine. One study’s 
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authors, Marcellin et al, admitted this fact and suggested longer length of follow-up to 
evaluate the sustained responses to peginterferon alfa-2a. Due to this limitation, quality of 
all studies was downgraded one level, using the GRADE system (Table 1). 
CONCLUSION 
It has been proven that peginterferon alfa-2a or alfa-2b could lead to HBsAg loss or 
seroconversion and sustained viral suppression in all patients with chronic hepatitis B, as 
well as HBeAg loss or seroconversion if patient has HBeAg positive.9-11 However, it is 
not clear about the benefits of adding lamivudine to peginterferon therapy, since 
peginterferon alone or with lamivudine showed similar responses and side effects. These 
studies suggested peginterferon alfa-2a or alfa-2b as first line therapy for CHB, but none 
of them recommended whether peginterferon should be used alone or with lamivudine. 
Based on the GRADE criteria, the quality of all studies are low, as discussed above and 
described in Table 1.  
More randomized controlled trials with longer length of follow-up are needed to 
evaluate the long-term responses of Hepatitis B virus to peginterferon (alfa-2a or alfa-2b) 
alone or with lamivudine, as well as the effects of adding lamivudine to peginterferon for 
treating CHB. Future randomized controlled trials investigating the efficacy and safety of 
peginterferon alfa-2b in HBeAg negative chronic hepatitis B would also be important for 
clinical practice and patient outcomes.  
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Table I: Characteristics of reviewed studies, GRADE profile, and summary of findings. Peginterferon alone or in combination 
with lamivudine in chronic hepatitis B treatment. 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
a  Length of follow-up was not sufficient (24 to 26 weeks) 
b  All studies were sponsored or funded by pharmaceutical companies, but authors stated that they had full access to data and actively involved in all steps of study from patients selection to manuscript of reports.  
Quality Assessment Summary of Findings 
Importance 
 Downgrade Criteria  Number of Patients/total patients Effect 
Quality  
No. of Studies Design Limitations Indirectness Imprecision Inconsistency Publication bias likely Study 
Peginterferon 
and 
Lamivudine 
combination 
therapy (x) 
Peginterferon 
and Placebo 
(y) 
Relative 
Risk  
(x/y) 
NNT 
HBV DNA Suppression 
3 
 
3 RCTs 
 
 Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies Bias likely
b 
Marcellin et al 79/179 76/177 1.02 100 
Low  Critical Lau et al 91/271 86/271 1.06 50 
Janssen et al 41/130 37/136 1.19 20 
HBsAg Seroconversion 
3 3 RCTs  
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies Bias likely
b 
Marcellin et al 3/179 5/177 0.61 91 
Low  Critical Lau et al 8/271 8/271 1 ∞ 
Janssen et al 9/130 7/136 0.54 50 
HBeAg Seroconversion 
2 2 RCTs Serious limitationsa 
No serious 
indirectness 
No serious 
imprecision  
No serious 
inconsistencies Bias likely
b 
Lau et al 74/271 87/271 0.84 20 
Low  Critical 
Janssen et al 38/130 39/136 1 ∞ 
HBsAg loss 
2 2RCTs Serious limitationsa 
No serious 
indirectness 
No serious 
imprecision  
No serious 
inconsistencies Bias likely
b 
Marcellin et al 5/179 7/177 0.7 83 
Low  Critical  
Janssen et al 9/130 9/136 1 ∞ 
Normalization of Alanine Aminotransferaminase Level    
3 3 RCTs  
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies Bias likely
b 
Marcellin et al 107/179 105/177 1.01 100 
Low  Critical Lau et al 106/271 111/271 0.95 50 
Janssen et al 46/130 44/136 1.09 33 
Histologic Response 
 
 
3 
 
 
3 RCTs 
 
 
Serious 
limitationsa 
 
No serious 
indirectness 
 
No serious 
imprecision No serious inconsistencies Bias likelyb 
Marcellin et al 68/179 85/177 0.79 10 
Low  
 
 
Critical Lau et al 112/271 102/271 1.08 33 
Janssen et al 25/52 a 31/58 a 0.91 20 
